{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:34:47Z","timestamp":1793885687359,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1245\/s10434-021-10983-2","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T16:03:36Z","timestamp":1635437016000},"page":"2104-2113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study"],"prefix":"10.1245","volume":"29","author":[{"given":"Vahan","family":"Kepenekian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"P\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bonnefoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alyami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Bakrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Rousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazim","family":"Benzerdjeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"10983_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","volume":"20","author":"SH Moolgavkar","year":"2009","unstructured":"Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005. Cancer Causes Control. 2009;20:935\u201344. https:\/\/doi.org\/10.1007\/s10552-009-9328-9.","journal-title":"Cancer Causes Control."},{"key":"10983_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/annonc\/mdl345","volume":"18","author":"P Boffetta","year":"2007","unstructured":"Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdl345.","journal-title":"Ann Oncol."},{"key":"10983_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/annonc\/mdl428","volume":"18","author":"TD Yan","year":"2007","unstructured":"Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827\u201334. https:\/\/doi.org\/10.1093\/annonc\/mdl428.","journal-title":"Ann Oncol."},{"key":"10983_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/jso.21177","volume":"99","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99:109\u201313. https:\/\/doi.org\/10.1002\/jso.21177.","journal-title":"J Surg Oncol."},{"key":"10983_CR5","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237\u201342. https:\/\/doi.org\/10.1200\/JCO.2009.23.9640.","journal-title":"J Clin Oncol."},{"key":"10983_CR6","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2014","unstructured":"Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2014;22:1686\u201393. https:\/\/doi.org\/10.1245\/s10434-014-3978-x.","journal-title":"Ann Surg Oncol."},{"key":"10983_CR7","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","volume":"21","author":"JT Miura","year":"2014","unstructured":"Miura JT, Johnston FM, Gamblin TC, Turaga KK. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21:3947\u201353. https:\/\/doi.org\/10.1245\/s10434-014-3803-6.","journal-title":"Ann Surg Oncol."},{"key":"10983_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1245\/s10434-019-08138-5","volume":"39","author":"L Bijelic","year":"2020","unstructured":"Bijelic L, Darcy K, Stodghill J, Tian C, Cannon T. Predictors and outcomes of surgery in peritoneal mesothelioma: an analysis of 2000 patients from the National Cancer Database. Ann Surg Oncol. 2020;39:576\u20139. https:\/\/doi.org\/10.1245\/s10434-019-08138-5.","journal-title":"Ann Surg Oncol."},{"key":"10983_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","volume":"47","author":"S Kusamura","year":"2020","unstructured":"Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2020;47:36\u201359. https:\/\/doi.org\/10.1016\/j.ejso.2020.02.011.","journal-title":"Eur J Surg Oncol."},{"key":"10983_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1245\/s10434-020-08324-w","volume":"19","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: management of peritoneal mesothelioma. Ann Surg Oncol. 2020;19:1\u20136. https:\/\/doi.org\/10.1245\/s10434-020-08324-w.","journal-title":"Ann Surg Oncol."},{"key":"10983_CR11","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1245\/s10434-017-6033-x","volume":"24","author":"F Le Roy","year":"2017","unstructured":"Le Roy F, Gelli M, Hollebecque A, et al. Conversion to complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol. 2017;24:3640\u20136. https:\/\/doi.org\/10.1245\/s10434-017-6033-x.","journal-title":"Ann Surg Oncol."},{"key":"10983_CR12","doi-asserted-by":"publisher","first-page":"20190010","DOI":"10.1515\/pp-2019-0010","volume":"4","author":"O Sgarbura","year":"2019","unstructured":"Sgarbura O, Gourgou S, Tosi D, et al. MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura Peritoneum. 2019;4:20190010. https:\/\/doi.org\/10.1515\/pp-2019-0010.","journal-title":"Pleura Peritoneum."},{"key":"10983_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1245\/s10434-019-07425-5","volume":"27","author":"YM Ali","year":"2020","unstructured":"Ali YM, Sweeney J, Shen P, et al. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on quality of life in patients with peritoneal mesothelioma. Ann Surg Oncol. 2020;27:117\u201323. https:\/\/doi.org\/10.1245\/s10434-019-07425-5.","journal-title":"Ann Surg Oncol."},{"key":"10983_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/14737140.2017.1340157","volume":"17","author":"E Fujimoto","year":"2017","unstructured":"Fujimoto E, Kijima T, Kuribayashi K, et al. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Rev Anticancer Ther. 2017;17:865\u201372. https:\/\/doi.org\/10.1080\/14737140.2017.1340157.","journal-title":"Expert Rev Anticancer Ther."},{"key":"10983_CR15","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2013.05.027.","journal-title":"Eur J Cancer."},{"key":"10983_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","volume":"65","author":"V Kepenekian","year":"2016","unstructured":"Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69\u201379. https:\/\/doi.org\/10.1016\/j.ejca.2016.06.002.","journal-title":"Eur J Cancer."},{"key":"10983_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","volume":"43","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43:1228\u201335. https:\/\/doi.org\/10.1016\/j.ejso.2017.01.009.","journal-title":"Eur J Surg Oncol."},{"key":"10983_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/BF01225271","volume":"118","author":"M Markman","year":"1992","unstructured":"Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547\u201350.","journal-title":"J Cancer Res Clin Oncol."},{"key":"10983_CR19","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1\u201311.","journal-title":"Cancer Treat Rep."},{"key":"10983_CR20","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1251::AID-CNCR27>3.0.CO;2-3","volume":"83","author":"DL Bartlett","year":"1998","unstructured":"Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer. 1998;83:1251\u201361.","journal-title":"Cancer."},{"key":"10983_CR21","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1046\/j.1365-2168.2000.01571.x","volume":"87","author":"G Sebbag","year":"2000","unstructured":"Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587\u201393. https:\/\/doi.org\/10.1046\/j.1365-2168.2000.01571.x.","journal-title":"Br J Surg."},{"key":"10983_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/jso.10255","volume":"83","author":"M Deraco","year":"2003","unstructured":"Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol. 2003;83:147\u201353. https:\/\/doi.org\/10.1002\/jso.10255.","journal-title":"J Surg Oncol."},{"key":"10983_CR23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ejso.2010.07.001","volume":"36","author":"MD Kluger","year":"2010","unstructured":"Kluger MD, Taub RN, Hesdorffer M, Jin Z, Chabot JA. Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: operative MORBIDITY and mortality in phase I and II trials. Eur J Surg Oncol. 2010;36:997\u20131003. https:\/\/doi.org\/10.1016\/j.ejso.2010.07.001.","journal-title":"Eur J Surg Oncol."},{"key":"10983_CR24","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1245\/s10434-019-08139-4","volume":"33","author":"JC Leinwand","year":"2019","unstructured":"Leinwand JC, Taub RN, Chabot JA, Kluger MD. Two-stage cytoreductive surgery and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: predictors of overall survival in an intention-to-treat series. Ann Surg Oncol. 2019;33:2539\u201347. https:\/\/doi.org\/10.1245\/s10434-019-08139-4.","journal-title":"Ann Surg Oncol."},{"key":"10983_CR25","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","volume":"26","author":"W Solass","year":"2012","unstructured":"Solass W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26:1849\u201355. https:\/\/doi.org\/10.1007\/s00464-012-2148-0.","journal-title":"Surg Endosc."},{"key":"10983_CR26","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20:e368\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(19)30318-3.","journal-title":"Lancet Oncol."},{"key":"10983_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1080\/02656736.2019.1704891","volume":"37","author":"A Davigo","year":"2020","unstructured":"Davigo A, Passot G, Vassal O, et al. PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model. Int J Hyperthermia. 2020;37:144\u201350. https:\/\/doi.org\/10.1080\/02656736.2019.1704891.","journal-title":"Int J Hyperthermia."},{"key":"10983_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12957-016-1008-0","volume":"14","author":"R Girshally","year":"2016","unstructured":"Girshally R, Demtr\u00f6der C, Albayrak N, Zieren J, Tempfer C, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2016;14:253. https:\/\/doi.org\/10.1186\/s12957-016-1008-0.","journal-title":"World J Surg Oncol."},{"key":"10983_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12885-018-4363-0","volume":"18","author":"U Giger-Pabst","year":"2018","unstructured":"Giger-Pabst U, Demtr\u00f6der C, Falkenstein TA, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer. 2018;18:442. https:\/\/doi.org\/10.1186\/s12885-018-4363-0.","journal-title":"BMC Cancer."},{"key":"10983_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejso.2019.06.028","volume":"47","author":"M Alyami","year":"2019","unstructured":"Alyami M, Mercier F, Siebert M, et al. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2019;47:128\u201333. https:\/\/doi.org\/10.1016\/j.ejso.2019.06.028.","journal-title":"Eur J Surg Oncol."},{"key":"10983_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijsu.2019.11.002","volume":"72","author":"R Agha","year":"2019","unstructured":"Agha R, Abdall-Razak A, Crossley E, et al. STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int J Surg. 2019;72:156\u201365. https:\/\/doi.org\/10.1016\/j.ijsu.2019.11.002.","journal-title":"Int J Surg."},{"key":"10983_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00280-018-3740-3","volume":"83","author":"M Siebert","year":"2019","unstructured":"Siebert M, Alyami M, Mercier F, et al. Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report. Cancer Chemother Pharmacol. 2019;83:425\u201330. https:\/\/doi.org\/10.1007\/s00280-018-3740-3.","journal-title":"Cancer Chemother Pharmacol."},{"key":"10983_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res."},{"key":"10983_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2018.05.001","volume":"150","author":"CB Tempfer","year":"2018","unstructured":"Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol. 2018;150:23\u201330. https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.001.","journal-title":"Gynecol Oncol."},{"key":"10983_CR35","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/his.13829","volume":"74","author":"W Solass","year":"2019","unstructured":"Solass W, Sempoux C, Carr NJ, et al. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology. 2019;74:1014\u201324. https:\/\/doi.org\/10.1111\/his.13829.","journal-title":"Histopathology."},{"key":"10983_CR36","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/his.14092","volume":"77","author":"N Benzerdjeb","year":"2020","unstructured":"Benzerdjeb N, Durieux E, Tantot J, et al. Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. Histopathology. 2020;77:548\u201359. https:\/\/doi.org\/10.1111\/his.14092.","journal-title":"Histopathology."},{"key":"10983_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29\u201342.","journal-title":"Ann Surg."},{"key":"10983_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/0002-9343(80)90103-5","volume":"68","author":"KH Antman","year":"1980","unstructured":"Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980;68:356\u201362.","journal-title":"Am J Med."},{"key":"10983_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/030089161109700105","volume":"97","author":"G Lainakis","year":"2011","unstructured":"Lainakis G, Zagouri F, Kastritis E, et al. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single-institution experience. Tumori J. 2011;97:25\u20139.","journal-title":"Tumori J."},{"key":"10983_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","volume":"47","author":"M Alyami","year":"2021","unstructured":"Alyami M, Bonnot P-E, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47:123\u201327. https:\/\/doi.org\/10.1016\/j.ejso.2020.05.021.","journal-title":"Eur J Surg Oncol"},{"key":"10983_CR41","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1007\/s00464-019-07076-3","volume":"17","author":"C Tavernier","year":"2019","unstructured":"Tavernier C, Passot G, Vassal O, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) might increase the risk of anastomotic leakage compared to HIPEC: an experimental study. Surg Endosc. 2019;17:2939\u201346. https:\/\/doi.org\/10.1007\/s00464-019-07076-3.","journal-title":"Surg Endosc."},{"key":"10983_CR42","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093\u2013100. https:\/\/doi.org\/10.1245\/s10434-012-2845-x.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10983-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10983-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10983-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T17:08:08Z","timestamp":1643821688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10983-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10983"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10983-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Olivier Glehen is a consultant for Gamida. The French network for the treatment of rare peritoneal malignancies (RENAPE) was sponsored by the French National Cancer Institute (INCa). There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}